Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1, single center, open-label, randomized, single-dose, two-way crossover study analyzing pharmacokinetic of Test Pediatric Formulation of Ezogabine (XEN496) in Healthy Adult Volunteers

Next Previous
Trial Profile

A phase 1, single center, open-label, randomized, single-dose, two-way crossover study analyzing pharmacokinetic of Test Pediatric Formulation of Ezogabine (XEN496) in Healthy Adult Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Retigabine (Primary)
  • Indications Early infantile epileptic encephalopathy 2
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Xenon Pharmaceuticals

Most Recent Events

  • 05 Apr 2022 Results assessing the effect of food on the pharmacokinetics of XEN496 and its N-acetyl metabolite in healthy volunteers, published in the Neurology and Therapy
  • 08 Dec 2020 Results evaluating pk of Retigabine presented at the 74th Annual Meeting of the American Epilepsy Society
  • 01 May 2020 Trial design, presented at the 72nd Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top